PARP-Inhibitor Combination Treatments for the Urologic Care Team Webcast (2025)

PARP-Inhibitor Combination Treatments for the Urologic Care Team will address PARP-Inhibitors in the rapidly changing castration resistant prostate cancer (CRPC) landscape for the urologic care team. This webcast is designed for the urologic care team to further address the identified educational gaps and barriers in advanced prostate cancer care and on the latest advancements in PARP-Inhibitor Combination Treatments.


ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

  • AstraZeneca

  • Merck & Co., Inc.

Target Audience

  • Urologists
  • APPs
  • Residents
  • Fellows
  • Young Urologists

Learning Objectives

At the conclusion of this CME activity, participants will be able to:

1. Apply the mechanism of action of PARP inhibitors and the rationale for using them in patients with advanced prostate cancer.
2. Recognize the role and importance of genetic testing in patients with mCRPC and the implications of germline mutations on response to therapy.
3. Identify best practices and utilize available guidelines for patients with mCRPC to optimize treatment success and oncologic outcomes.
4. Recognize when to use PARP inhibitors as monotherapy, the rationale and indications for combination therapy, and appropriate treatment sequencing.
5. Successfully counsel patients on the possible adverse events associated with PARP inhibitor therapies alone or in combination.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
04/30/2025
Course expires: 
04/30/2026
Rating: 
0

Welcome
Kristen Scarpato, MD, MPH, FACS

Case Discussions
Kristen Scarpato, MD, MPH, FACS; Alicia Morgans, MD, MPH, FASCO & Kelvin Moses, MD, PhD, FACS

NameCompany NameRelationship TypeEnd Date
Morgans, AliciaAstra ZenecaConsultant or AdvisorCurrent
MerckConsultant or AdvisorCurrent
PfizerConsultant or AdvisorCurrent
GSKConsultant or AdvisorCurrent
Exact SciencesConsultant or AdvisorCurrent
Moses, Kelvin A.No relevant financial relationships to disclose
Scarpato, Kristen R.No relevant financial relationships to disclose

EDUCATION COUNCIL DISCLOSURE

PDF icon Education Council Disclosures_June 2024.pdf

COI REVIEW WORK GROUP DISCLOSURES

PDF icon COI Review Workgroup Disclosures_June 2024.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

AUA ACCREDITATION INFORMATION

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.00 hours

Release Date: April, 2025
Expiration Date: April, 2026

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification relevant financial relationships that result in of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES


DISCLAIMER:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

REPRODUCTION PERMISSION: 

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.

Registration for this webcast is complimentary. 

To begin the course, click on the TAKE COURSE button.